Correlation between docetaxel-induced skin toxicity and the use of steroids and H 2 blockers: A multi-institution survey

Breast Cancer Research and Treatment

Volumn 130, Issue 2, 2011, Pages 627-634

  Kawaguchi, K ^a,b   Ishiguro, H ^a   Morita, S ^c   Nakamura, S ^d   Ohno, S ^e   Masuda, N ^f   Iwata, H ^g   Aogi, K ^h   Kuroi, K ⁱ   Toi, M ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^d SHOWA UNIVERSITY HOSPITAL   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f OSAKA NATIONAL HOSPITAL   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION   (Japan)

ⁱ TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

CYP3A4; Docetaxel; Drug exposure; Facial erythema; H 2 blocker; Hand foot syndrome

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DEXAMETHASONE; DOCETAXEL; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LAFUTIDINE; RANITIDINE; STEROID; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG INDUCED DISEASE; DRUG METABOLISM; FACE EDEMA; FACE ERYTHEMA; HAND FOOT SYNDROME; HUMAN; INCIDENCE; OBSERVATIONAL STUDY; PREMEDICATION; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SKIN TOXICITY;

ACETAMIDES; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DEXAMETHASONE; ERYTHEMA; FAMOTIDINE; FEMALE; GLUCOCORTICOIDS; HAND-FOOT SYNDROME; HISTAMINE H2 ANTAGONISTS; HUMANS; INCIDENCE; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PIPERIDINES; PYRIDINES; QUESTIONNAIRES; RANITIDINE; RETROSPECTIVE STUDIES; STEROIDS; TAXOIDS;

EID: 82955212944     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1641-9     Document Type: Article

References (28)

1. Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, Groult V, Murawsky M, Cold S (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24(31):4963-4970. doi: 10.1200/JCO.2005.05.0294 (Pubitemid 46631397)
2. Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Bara-jas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178-1184. doi:10.1200/JCO.2005.09.102 (Pubitemid 46202274)
3. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15(9):3149-3155 (Pubitemid 27377507)
4. Suh Y, Chun CC, Oh S, Song B, Jung S (2008) Comparison of one-day premedication for TAC chemotherapy with three-day regimen for node-positive breast cancer patients. J Clin Oncol 26: 15s. Abstr 621
5. Mc Cune JS, Hawke RL, Le Cluyse EL, Gillenwater HH, Hamil-ton G, Ritchie J, Lindley C (2000) In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Phar-macol Ther 68(4):356-366. doi:10.1067/mcp.2000. 110215
6. Ishiguro H, Yano I, Toi M (2009) Important drug interactions for clinical oncologists. In: Caldwell GW, Atta-ur-Rahman Yan Z, Choudhary MI et al (eds) Frontiers in drug design and discovery, vol 4. Bentham Science Publishers, Dubai, pp 97-121
7. Murray LS, Jodrell DI, Morrison JG, Cook A, Kerr DJ, Whiting B, Kaye SB, Cassidy J (1998) The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clin Oncol (R Coll Radiol) 10(1):35-38 (Pubitemid 28112375)
8. Harvey VJ, Slevin ML, Dilloway MR, Clark PI, Johnston A, Lant AF (1984) The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol 18(3):421-430 (Pubitemid 14033829)
9. Koch M, Dezi A, Ferrario F, Capurso I (1996) Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clini-cal trials. Arch Intern Med 156(20):2321-2332 (Pubitemid 26395546)
10. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthra-cycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812-2823 (Pubitemid 34651510)
11. Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du Bois A, Kreienberg R, Mayordomo JI, Anton A, Harrison M, Jones A, Carrasco E, Vaury AT, Frimodt-Moller B, Fumoleau P (2009) Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27(11):1753-1760. doi:10.1200/JCO. 2007.15.8485
12. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56(6):1296-1302 (Pubitemid 26080972)
13. Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36(2):99-114 (Pubitemid 29121684)
14. Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A (2004) Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75(5):448-454. doi:10.1016/j.clpt.2004.01.001 (Pubitemid 38534565)
15. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54(10):1271-1294 (Pubitemid 35284253)
16. Felici A, Verweij J, Sparreboom A (2002) Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 38(13):1677-1684
17. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16(1):187-196 (Pubitemid 28041598)
18. Scotte F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu JM, Oudard S (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23(19):4424-4429. doi:10.1200/JCO.2005.15.651 (Pubitemid 46207017)
19. Battegay EJ (1995) Angiogenesis: mechanistic insights, neovas-cular diseases, and therapeutic prospects. J Mol Med 73(7): 333-346
20. Wasner G, Hilpert F, Schattschneider J, Binder A, Pfisterer J, Baron R (2002) Docetaxel-induced nail changes-a neurogenic mechanism: a case report. J Neurooncol 58(2):167-174 (Pubitemid 34784847)
21. Mukohara T, Takeda K, Miyazaki M, Takifuji N, Terakawa K, Negoro S (2001) Japanese experience with second-line chemo-therapy with low-dose (60 mg/m ) docetaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Phar-macol 48(5):356-360 (Pubitemid 33027991)
22. Semb KA, Aamdal S, Oian P (1998) Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16(10):3426-3432 (Pubitemid 28481642)
23. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8(7):1263-1268 (Pubitemid 20195638)
24. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, Mann SG, Simon TJ, Sturrock RD, Russell RI (1996) Famo-tidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334(22): 1435-1439 (Pubitemid 26157439)
25. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, Mc Leod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharma-ceutical Research and Manufacturers of America (Ph RMA) per-spective. Drug Metab Dispos 31(7):815-832. doi:10.1124/dmd. 31.7.815 (Pubitemid 36759050)
26. de Jonge ME, Huitema AD, van Dam SM, Rodenhuis S, Beijnen JH (2005) Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechlor-oethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin. Ther Drug Monit 27(6):756-765 (Pubitemid 44391731)
27. Buzdar AU, Cuzick J (2006) Anastrozole as an adjuvant endo-crine treatment for postmenopausal patients with breast cancer: emerging data. Clin Cancer Res 12(3 Pt 2):1037s-1048s. doi: 10.1158/1078-0432 (Pubitemid 43259841)
28. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministra-tion of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95(23):1758-1764 (Pubitemid 38008898)